NeuroVasx, a catheter and implant technologies company to treat acute stroke, aneurysms and other cerebrovascular disorders, has completed a private placement of common stock in the amount of $8.5 million with Miller Johnson Steichen Kinnard of Minneapolis, Minn., and the Stephens Group of Little Rock, Ark.
Specific terms of the financing were not disclosed.
The Maple Grove, Minn.-based company also announced completion of follow-up on 20 patients treated with the cPAX Aneurysm Treatment System in a clinical study which was completed in May. The company is scheduled to announce the study results at the 2008 International Stroke Conference held in New Orleans, La. in February.